Find the investigators, sites, and systems first

Investigator, trial-site, and system-investment intelligence built on momentum signals — not directory look-backs.

Who this serves

Major pharma, biotech, CROs, biomanufacturers, medical device, diagnostics.

What this means for your strategy

Build advisory boards and KOL plans around rising-star investigators — ranked by funding momentum and peer quartile, not historical citations
Select and rescue trial sites on demonstrated site-level throughput from a daily-refreshed national panel
Spot which health systems are investing in your category — hiring, capacity, and capital signals — before it is public news

The quality behind it

Investigator momentum triangulated across public funding, publication, patent, and trial registries on publisher cadence
Site-grain trial panel refreshed daily — recruiting status and history preserved snapshot over snapshot
Every signal resolved to investigator identity and system ownership, so intelligence rolls up to the account your team calls on

Why AI alone can’t replicate it

Momentum is longitudinal — it exists only because every vintage was captured and preserved; the public web keeps only today
Investigator identity resolution across multiple public registries takes a curated match process — generic entity matching quietly mislabels
Directory look-backs describe who was famous; a forward-looking momentum signal must be assembled, governed, and analyst-gated

By the numbers

3,900+research organizations ranked by topic momentum, FY2018–25

Dailyrefresh of the national trial-site panel, with history preserved

5 signalsfunding, publications, trials, patents, abstracts — per institution

600+health systems monitored daily for hiring investment signals

Editions for this seat